<DOC>
	<DOC>NCT02292615</DOC>
	<brief_summary>In this prospective cohort study, patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers) and patients with suspicious recurrent gynecologic cancers will be enrolled. The study period is two years and the estimated patient number is about 220. Patients will undergo image study before and after treatment. The diagnostic accuracy of MR-PET in cancer staging and the potential image biomarkers to monitor treatment response and predict treatment outcome will be investigated.</brief_summary>
	<brief_title>Application of Integrated MR-PET in Patients With Gynecologic Cancers</brief_title>
	<detailed_description />
	<criteria>1. Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers). 2. Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers). 3. Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy. 1. Age &lt;20 or &gt;90 years old 2. Contraindication for MRI: 3. Contraindication for MR contrast medium (Cre &gt; 2.0) 4. History of other malignancy 5. Prior arthroplasty of hip or pelvic bone surgery with metallic fixation (may cause artifacts on MRI) 6. Pregnant or lactating women</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>